Calculated PRA: A process whose time has come or 'Déjàvu' all over again?

American Journal of Transplantation

Volumn 11, Issue 4, 2011, Pages 650-651

  Bray, R A ^a   Murphey, C ^b   Schaub, S ^c  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b Southwest Immunodiagnostics Inc ^*  (United States)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

CPRA; highly sensitized; organ allocation; unacceptable antigens; virtual cross match

Indexed keywords

EPITOPE; HLA ANTIGEN;

ALLELE; ANTIBODY DETECTION; ANTIBODY MEDIATED REJECTION; ANTIBODY SPECIFICITY; DONOR SELECTION; EDITORIAL; GRAFT REJECTION; GRAFT SURVIVAL; HLA TYPING; HUMAN; ORGAN DONOR; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS;

EID: 79953252065     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03452.x     Document Type: Editorial

References (6)

1. Cecka M, Kucheryavaya A, Reinsmoen N, Leffell M,. Am J Transplant 2010; 10: 1-6.
2. Delmonico F, Fuller A, Cosimi A, et al,. New approaches to donor crossmatching and successful transplantation of highly sensitized patients. Transplantation 1983; 36: 629-633. (Pubitemid 14216270)
3. Oldfather J, Anderson C, Phelan D, Cross D, Luger A, Rodey G,. Predicting of crossmatch outcome in highly sensitized dialysis patients based on identification of serum HLA antibodies. Transplantation 1986; 42: 267-270. (Pubitemid 16020749)
4. Bingaman AW, Murphey CL, Palma-Vargas J, Wright F,. A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation. Transplantation 2008; 86: 1864-1868.
5. Claas FH, Rahmel A, Doxiadis II,. Enhanced kidney allocation to highly sensitized patients by the acceptable mismatch program. Transplantation 2009; 88: 447-452.
6. Gebel HM, Bray RA,. The evolution and clinical impact of human leukocyte antigen technology. Curr Opin Nephrol Hypertens 2010; 19: 598-602.